First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir | Zendy

Marit GA van Vonderen | Zendy; Paul Lips | Zendy; Michiel A. van Agtmael | Zendy; Elly A. Hassink | Zendy; Kees Brinkman | Zendy; Suzanne E. Geerlings | Zendy; Jussi Sutinen | Zendy; Matti Ristola | Zendy; Sven A. Danner | Zendy; Peter Reiss | Zendy

Open Access

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

Author(s) -

Marit GA van Vonderen,

Paul Lips,

Michiel A. van Agtmael,

Elly A. Hassink,

Kees Brinkman,

Suzanne E. Geerlings,

Jussi Sutinen,

Matti Ristola,

Sven A. Danner,

Peter Reiss

Publication year - 2009

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e32832c4947

Subject(s) - ritonavir , lopinavir , lopinavir/ritonavir , medicine , lamivudine , zidovudine , urology , bone mineral , nevirapine , deoxypyridinoline , bone remodeling , gastroenterology , creatinine , endocrinology , osteocalcin , viral load , osteoporosis , chemistry , human immunodeficiency virus (hiv) , virology , alkaline phosphatase , antiretroviral therapy , hepatitis b virus , biochemistry , virus , viral disease , enzyme

We studied changes in bone mineral density (BMD) and bone turnover after initiation of combination antiretroviral therapy (cART) and the contribution of zidovudine/lamivudine (ZDV/3TC) in particular.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research